1-3 of 3
Karoline Veronika Gleixner, MD
Close
Sort by
Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4227.
https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227
Published: 2017
Journal Articles

Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.

Karoline Veronika Gleixner, MD, Matthias Mayerhofer, MD, Gregor Hörmann, Karina Schuch, Sabine Cerny-Reiterer, MD, Barbara Peter, M.V.M, Harald Herrmann, MD, Winfried F. Pickl, MD, Christian Sillaber, Peter Valent, MD
Journal: Blood
Blood (2009) 114 (22): 1717.
https://doi.org/10.1182/blood.V114.22.1717.1717
Published: 2009
Journal Articles

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Karoline Veronika Gleixner, MD, Lily L Remsing Rix, Christian Baumgartner, Uwe Rix, Alexander Gruze, Renata Anna Meyer, M.D., Winfried F. Pickl, MD, Christian Sillaber, Martin Augustin, Jeff Till, Giulio Superti-Furga, Peter Valent, MD
Journal: Blood
Blood (2008) 112 (11): 3195.
https://doi.org/10.1182/blood.V112.11.3195.3195
Published: 2008